Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

⁶¹ Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging.

Autor: Basaco Bernabeu T; Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland., Mansi R; Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland., Del Pozzo L; Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland., Zanger S; Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland., Gaonkar RH; Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland., McDougall L; Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland., De Rose F; Nuclidium AG, Basel, Switzerland., Jaafar-Thiel L; Nuclidium AG, Basel, Switzerland., Herz M; Department of Nuclear Medicine, Technical University of Munich, Munich, Germany.; Bavarian Cancer Research Center, Munich, Germany., Eiber M; Department of Nuclear Medicine, Technical University of Munich, Munich, Germany.; Bavarian Cancer Research Center, Munich, Germany., Ulaner GA; Molecular Imaging and Therapy, Hoag Family Cancer Institute, Irvine, California; and.; Departments of Radiology and Translational Genomics, University of Southern California, Los Angeles, California., Weber WA; Department of Nuclear Medicine, Technical University of Munich, Munich, Germany.; Bavarian Cancer Research Center, Munich, Germany., Fani M; Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland; melpomeni.fani@usb.ch.

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 Sep 03; Vol. 65 (9), pp. 1427-1434. Date of Electronic Publication: 2024 Sep 03.